ImageneBio Inc (IMA) Research

ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.

Market snapshot

Symbol
IMA
Price
$6.00
Day change
+5.45%
Market cap
$67.7M
P/E ratio
-1.49x
52-week range
3.94-18
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 1 month
Analyst price target
$1.33

Recent news

  • ImageneBio $30 Million Private Placement Ignites Stock

    ImageneBio is a clinical-stage biopharmaceutical company focused on developing therapeutics for immunological, autoimmune and inflammatory diseases.

Peer companies

  • Artiva Biotherapeutics, Inc. (ARTV)
  • Connect Biopharma Holdings Limited (CNTB)
  • Context Therapeutics Inc. (CNTX)
  • InflaRx N.V. (IFRX)
  • Kalaris Therapeutics Inc (KLRS)
  • Metagenomi, Inc. Common Stock (MGX)
  • Ovid Therapeutics Inc. (OVID)
  • Quince Therapeutics, Inc. (QNCX)

Recent insider activity

  • Wang Jonathan Jian — A-Award (15600 shares) on 2026-06-16
  • Stampacchia Otello — A-Award (15600 shares) on 2026-06-16
  • SLATTERY JOSEPH P — A-Award (15600 shares) on 2026-06-16
  • Bonita David P — A-Award (15600 shares) on 2026-06-16
  • Lally Robert B — trade (0 shares) on 2026-03-20

Open ImageneBio Inc (IMA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.